Lopinavir + Ritonavir interactions

Checked as Lopinavir + Ritonavir in this data source.

Full monograph for Lopinavir + Ritonavir Check it against another medicine

Medicines

720 documented

Severity

Mechanism

Medicines documented to interact with Lopinavir + Ritonavir, worst severity first.
Medicine	Severity	Mechanism	Effect	Sources
Abemaciclibvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of abemaciclib and its pharmacologically active…	4 sources — open the full entry
Acalabrutinibvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of acalabrutinib, which is primarily metabolized by…	4 sources — open the full entry
Alfuzosin Hydrochloridevia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of alfuzosin, which is primarily metabolized by the…2 documented mechanisms	13 sources — open the full entry
Amiodarone Hydrochloridevia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Class IA (e.g., disopyramide, quinidine, procainamide) and class III (e.g., amiodarone, dofetilide, sotalol) antiarrhythmic agents can cause dose-related…2 documented mechanisms	37 sources — open the full entry
Amisulpridevia Lopinavir	Major	Synergy	Amisulpride can cause dose- and concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the…2 documented mechanisms	4 sources — open the full entry
Amlodipine Besilate + Atorvastatinvia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of…3 documented mechanisms	109 sources — open the full entry
Apalutamidevia Lopinavir, Ritonavir	Major	Metabolism	Coadministration with apalutamide may decrease the plasma concentrations of ritonavir and result in a potential loss of virologic response. The proposed…2 documented mechanisms	10 sources — open the full entry
Apixabanvia Ritonavir	Major	Absorption · Metabolism	Coadministration with potent inhibitors of CYP450 3A4 that can also inhibit P-glycoprotein (P-gp) may significantly increase the plasma concentrations of…	6 sources — open the full entry
Arsenic Trioxidevia Lopinavir	Major	Synergy	Arsenic trioxide can cause QT interval prolongation and complete atrioventricular block. Theoretically, coadministration with other agents that can prolong the…2 documented mechanisms	6 sources — open the full entry
Artemether + Lumefantrinevia Ritonavir	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations of artemether and lumefantrine, both of which are primarily metabolized…2 documented mechanisms	9 sources — open the full entry
Atorvastatin + Ezetimibevia Ritonavir	Major	Metabolism · Unknown	Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of…2 documented mechanisms	103 sources — open the full entry
Atorvastatin Calciumvia Ritonavir	Major	Metabolism	Protease inhibitors (PIs), particularly ritonavir, may significantly increase the plasma concentrations of atorvastatin. The mechanism is PI inhibition of…	103 sources — open the full entry
Avanafilvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of avanafil, which is primarily metabolized by the…	10 sources — open the full entry
Axitinibvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of axitinib, which is primarily metabolized by the…	7 sources — open the full entry
Azelastine Hydrochloride + Fluticasone Propionatevia Ritonavir	Major	Metabolism	Coadministration with ritonavir may significantly increase the systemic exposure to fluticasone following intranasal administration or oral inhalation. The…	35 sources — open the full entry
Betrixabanvia Ritonavir	Major	Others	Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the plasma concentrations of betrixaban, which is a substrate of the…	11 sources — open the full entry
Bosentan Monohydratevia Lopinavir, Ritonavir	Major	Metabolism · Others	Coadministration with the pharmacokinetic boosters cobicistat and ritonavir may significantly increase the plasma concentrations of bosentan, particularly…2 documented mechanisms	15 sources — open the full entry
Brexpiprazolevia Ritonavir	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 and/or 2D6 may significantly increase the plasma concentrations of brexpiprazole, which is metabolized by these…	5 sources — open the full entry
Brigatinibvia Lopinavir, Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of brigatinib, which is partially metabolized by the…2 documented mechanisms	5 sources — open the full entry
BudesonideInhaler Nebuliser Suspension Tabletvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic bioavailability of budesonide, which undergoes extensive…	19 sources — open the full entry
Budesonide + Formoterol Fumaratevia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic bioavailability of budesonide, which undergoes extensive…3 documented mechanisms	79 sources — open the full entry
Budesonide + Glycopyrronium Bromide + Formoterol Fumaratevia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the systemic bioavailability of budesonide, which undergoes extensive…3 documented mechanisms	79 sources — open the full entry
Cabozantinibvia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Cabozantinib can cause prolongation of the QT interval.Theoretically, coadministration with other agents that can prolong the QT interval may result in…2 documented mechanisms	9 sources — open the full entry
Capmatinib Hydrochloridevia Ritonavir	Major	Metabolism	Coadministration of capmatinib with strong CYP450 3A4 inhibitors may increase the risk and severity of capmatinib adverse effects, such as interstitial lung…	3 sources — open the full entry
Carbamazepinevia Lopinavir, Ritonavir	Major	Metabolism	INTERVAL: Coadministration of lopinavir-ritonavir with carbamazepine may result in decreased plasma concentrations of lopinavir and increased plasma…3 documented mechanisms	51 sources — open the full entry
Cariprazinevia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of cariprazine and its major active metabolite…	5 sources — open the full entry
Ceritinibvia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Ceritinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval…2 documented mechanisms	10 sources — open the full entry
Chloroquine Phosphatevia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Chloroquine and hydroxychloroquine can cause dose-related prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong…3 documented mechanisms	46 sources — open the full entry
Cilostazolvia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Coadministration with inhibitors of CYP450 3A4 and/or 2C19 may increase the plasma concentrations of cilostazol and or its pharmacologically active…2 documented mechanisms	17 sources — open the full entry
Citalopram Hydrobromidevia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Citalopram can cause dose-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT interval may…3 documented mechanisms	28 sources — open the full entry
Clopidogrel + Aspirinvia Ritonavir	Major	Metabolism · Unknown	Coadministration with cobicistat or ritonavir may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation to a…2 documented mechanisms	8 sources — open the full entry
Clopidogrel Bisulphatevia Ritonavir	Major	Metabolism	Coadministration with cobicistat or ritonavir may reduce the efficacy of clopidogrel, whose antiplatelet effect is dependent in part on bioactivation to a…	8 sources — open the full entry
Clozapinevia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Clozapine has the potential to prolong QT interval of the electrocardiogram. Theoretically, coadministration with other agents that can cause QT prolongation…3 documented mechanisms	25 sources — open the full entry
Colchicinevia Ritonavir	Major	Metabolism	Coadministration with inhibitors of CYP450 3A4 may significantly increase the serum concentrations of colchicine, which is primarily metabolized by the…	44 sources — open the full entry
Crizotinibvia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Crizotinib can cause concentration-dependent prolongation of the QT interval. Theoretically, coadministration with other agents that can prolong the QT…2 documented mechanisms	7 sources — open the full entry
Cyclosporine (Oral)via Lopinavir, Ritonavir	Major	Absorption · Metabolism	Coadministration with protease inhibitors (PIs), especially ritonavir, may significantly increase the blood concentrations of cyclosporine. The risk of nephro-…2 documented mechanisms	30 sources — open the full entry
Daclatasvirvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by…	4 sources — open the full entry
Daclatasvir + Sofosbuvirvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of daclatasvir, which is primarily metabolized by…	4 sources — open the full entry
Darifenacinvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of darifenacin, which is partially metabolized by…	7 sources — open the full entry
Dasatinibvia Lopinavir, Ritonavir	Major	Metabolism · Synergy	Coadministration with inhibitors of CYP450 3A4 may increase the plasma concentrations and pharmacologic effects of dasatinib, which is primarily metabolized by…2 documented mechanisms	13 sources — open the full entry
Deflazacortvia Ritonavir	Major	Metabolism	Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of 21-desdeflazacort, the active…	3 sources — open the full entry
Docetaxel Trihydratevia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 or dual CYP450 3A4 and P-glycoprotein (P-gp) inhibitors may significantly increase the plasma…	21 sources — open the full entry
Drospirenonevia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…	9 sources — open the full entry
Drospirenone + Estetrolvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…	9 sources — open the full entry
Drospirenone + Estradiolvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms	17 sources — open the full entry
Drospirenone + Ethinyl Estradiol0.02 mg 0.03 mgvia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms	48 sources — open the full entry
Drospirenone + Ethinyl Estradiol + Levomefolatevia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of drospirenone which is primarily metabolized by…2 documented mechanisms	48 sources — open the full entry
Econazole Nitrate + Triamcinolone Acetonidevia Ritonavir	Major	Metabolism	Coadministration with potent inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of triamcinolone.	14 sources — open the full entry
Efavirenzvia Lopinavir, Ritonavir	Major	Metabolism · Others	Coadministration with efavirenz may decrease the plasma concentrations of lopinavir, even in the presence of low-dose ritonavir as a pharmacokinetic booster…3 documented mechanisms	17 sources — open the full entry
Elacestrantvia Ritonavir	Major	Metabolism	Coadministration with potent or moderate inhibitors of CYP450 3A4 may significantly increase the plasma concentrations of elacestrant, which is primarily…	1 sources — open the full entry

Food & lifestyle

high-fat foods
Moderate
Absorption
Administration with food may modestly affect the bioavailability of ritonavir from the various available formulations. When the oral solution was given under nonfasting conditions, peak ritonavir concentrations decreased 23% and the extent of absorption decreased 7% relative to fasting conditions. Dilution of the oral solution (within one hour of dosing) with 240 mL of chocolate milk or a nutritional supplement (Advera or Ensure) did not significantly affect the extent and rate of ritonavir absorption. When a single 100 mg dose of the tablet was administered with a high-fat meal (907 kcal; 52% fat, 15% protein, 33% carbohydrates), approximately 20% decreases in mean peak concentration (Cmax) and systemic exposure (AUC) were observed relative to administration after fasting. Similar decreases in Cmax and AUC were reported when the tablet was administered with a moderate-fat meal. In contrast, the extent of absorption of ritonavir from the soft gelatin capsule formulation was 13% higher when administered with a meal (615 KCal; 14.5% fat, 9% protein, and 76% carbohydrate) relative to fasting.
What to do: Ritonavir should be taken with meals to enhance gastrointestinal tolerability.
1 source
1. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical (2001):

Conditions

Conditions in which Lopinavir + Ritonavir needs care, as documented in this source.

Hemophilia A
Major
There have been postmarketing reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in types A and B hemophiliac patients treated with protease inhibitors. However, a causal relationship has not been established. In some patients, additional Factor VIII was given. In more than half of the reported cases, protease inhibitor therapy was continued or reintroduced following an interruption. Hemophiliacs and patients with other coagulation defects should be monitored closely for bleeding during protease inhibitor therapy.
11 sources
1. "Product Information. Invirase (saquinavir)." Roche Laboratories (2001):
2. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical (2001):
3. "Product Information. Crixivan (indinavir)." Merck & Co., Inc (2001):
4. "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc (2001):
5. "Product Information. Agenerase (amprenavir)." Glaxo Wellcome (2001):
6. "Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical (2001):
7. "Product Information. Fortovase (saquinavir)." Roche Laboratories (2001):
8. "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb (2003):
Show all 11 sourcesShow fewer sources
1. "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline (2003):
2. "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim (2005):
3. "Product Information. Prezista (darunavir)." Ortho Biotech Inc (2006):
Liver Diseases
Major
Hepatotoxicity, including jaundice, hepatitis and hepatic transaminase elevations exceeding five times the upper limit of normal, has been reported in patients receiving ritonavir alone and in combination with nucleoside reverse transcriptase inhibitors or other protease inhibitors. In addition, ritonavir is primarily metabolized by the liver and may accumulate in patients with hepatic impairment. Therapy with ritonavir should be administered cautiously in patients with preexisting liver disease, liver enzyme abnormalities, or hepatitis. Ritonavir is not recommended for patients with severe hepatic impairment.
5 sources
1. Markowitz M, Saag M, Powderly WG, Hurley AM, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, et al. "A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection." N Engl J Med 333 (1995): 1534-9
2. Danner SA, Carr A, Leonard JM, Lehman LM, Gudiol F, Gonzales J, Raventos A, Rubio R, Bouza E, Pintado V, et al. "A short-term study of the safety, pharmacokinetics, and efficacy of ritonavir, an inhibitor of HIV-1 protease. European-Australian Collaborative Ritonavir Study Group." N Engl J Med 333 (1995): 1528-33
3. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical (2001):
4. Sommadossi JP "HIV protease inhibitors: pharmacologic and metabolic distinctions." AIDS 13 (1999): s29-40
5. Pai VB, Koranyi K, Nahata MC "Acute hepatitis and bleeding possibly induced by zidovudine and ritonavir in an infant with HIV infection." Pharmacotherapy 20 (2000): 1135-40
Heart Block
Moderate
Ritonavir may prolong the PR interval in some patients. Post marketing cases of second or third degree atrioventricular block have been reported. Ritonavir should be administered cautiously in patients with underlying structural heart disease, preexisting conduction abnormalities, ischemic heart disease, and cardiomyopathies as these patients might be at increased risk for developing cardiac conduction abnormalities.
1 source
1. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical (2001):
Hyperglycemia
Moderate
New onset diabetes mellitus, exacerbation of preexisting diabetes mellitus, glucose intolerance, hyperglycemia, and some cases of diabetic ketoacidosis have been reported during postmarketing surveillance in HIV-infected patients treated with protease inhibitors (PIs). In some cases, glucose abnormalities/hyperglycemia persisted despite discontinuation of PI therapy. Frequently, insulin resistance may accompany fat redistribution and serum lipid elevations in what is collectively termed the HIV-associated lipodystrophy syndrome. Although a causal relationship has not been established, these metabolic disturbances have most often occurred in HIV-infected patients during treatment with potent antiretroviral regimens containing PIs. Monitoring patients for hyperglycemia, new onset diabetes mellitus, or exacerbation of diabetes mellitus should be considered during PI therapy. Dosage adjustments in insulin or oral hypoglycemic medications may be necessary in patients with diabetes.
23 sources
1. "Product Information. Invirase (saquinavir)." Roche Laboratories (2001):
2. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical (2001):
3. "Product Information. Crixivan (indinavir)." Merck & Co., Inc (2001):
4. "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc (2001):
5. Dube MP, Johnson DL, Currier JS, Leedom JM "Protease inhibitor-associated hyperglycaemia." Lancet 350 (1997): 713-4
6. Walli R, Demant T "Impaired glucose tolerance and protease inhibitors." Ann Intern Med 129 (1998): 837-8
7. "Product Information. Agenerase (amprenavir)." Glaxo Wellcome (2001):
8. Mauss S, Wolf E, Jaeger H "Impaired glucose tolerance in HIV-positive patients receiving and those not receiving protease inhibitors." Ann Intern Med 130 (1999): 162-3
Show all 23 sourcesShow fewer sources
1. Kaufman MB, Simionatto C "A review of protease inhibitor-induced hyperglycemia." Pharmacotherapy 19 (1999): 114-7
2. Struble K, Piscitelli SC "Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients." Am J Health Syst Pharm 56 (1999): 2343-8
3. Qaqish RB, Fisher E, Rublein J, Wohl DA "HIV-associated lipodystrophy syndrome." Pharmacotherapy 20 (2000): 13-22
4. Pujol RM, Domingo P, XavierMatiasGuiu, Francia E, Sanbeat MA, Alomar A, Vazquez G "HIV-1 protease inhibitor-associated partial lipodystrophy: Clinicopathologic review of 14 cases." J Am Acad Dermatol 42 (2000): 193-8
5. Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6
6. Carr A "HIV protease inhibitor-related lipodystrophy syndrome." Clin Infect Dis 30 (2000): s135-42
7. "Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical (2001):
8. "Product Information. Fortovase (saquinavir)." Roche Laboratories (2001):
9. Hardy H, Esch LD, Morse GD "Glucose disorders associated with HIV and its drug therapy." Ann Pharmacother 35 (2001): 343-51
10. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C "Metabolic effects of indinavir in healthy HIV-seronegative men." Aids 15 (2001): f11-8
11. "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb (2003):
12. Brambilla AM, Novati R, Calori G, et al. "Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals." AIDS 17 (2003): 1993-5
13. "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline (2003):
14. "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim (2005):
15. "Product Information. Prezista (darunavir)." Ortho Biotech Inc (2006):
Hyperlipidemias
Moderate
Hyperlipidemia has been observed in 10% of patients receiving ritonavir during clinical trials. Increases of 30% to 40% from baseline have been reported for total cholesterol and 200% to 300% or more for triglycerides. These effects have also been reported during postmarketing experience with other protease inhibitors (PIs) but may be the most dramatic with ritonavir. The clinical significance of these elevations is unclear. Severe hyperlipidemia is known to sometimes cause pancreatitis. In addition, some patients have reportedly developed symptomatic atherosclerosis and coronary artery disease after initiating PI treatment. Patients with preexisting hyperlipidemia may require closer monitoring during PI therapy, and adjustments made accordingly in their lipid-lowering regimen. PI therapy should be administered cautiously in patients with coronary artery disease or a history of ischemic heart disease.
19 sources
1. "Product Information. Invirase (saquinavir)." Roche Laboratories (2001):
2. "Product Information. Norvir (ritonavir)." Abbott Pharmaceutical (2001):
3. "Product Information. Crixivan (indinavir)." Merck & Co., Inc (2001):
4. "Product Information. Viracept (nelfinavir)." Agouron Pharma Inc (2001):
5. Sullivan AK, Feher MD, Nelson MR, Gazzard BG "Marked hypertriglyceridaemia associated with ritonavir therapy." AIDS 12 (1998): 1393-4
6. Karmochkine M, Raguin G "Severe coronary artery disease in a young HIV-infected man with no cardiovascular risk factor who was treated with indinavir." AIDS 12 (1998): 2499
7. "Product Information. Agenerase (amprenavir)." Glaxo Wellcome (2001):
8. Segerer S, Bogner JR, Walli R, Loch O, Goebel FD "Hyperlipidemia under treatment with proteinase inhibitors." Infection 27 (1999): 77-81
Show all 19 sourcesShow fewer sources
1. Echevarria KL, Hardin TC, Smith JA "Hyperlipidemia associated with protease inhibitor therapy." Ann Pharmacother 33 (1999): 859-63
2. Flynn TE, Bricker LA "Myocardial infarction in HIV-infected men receiving protease inhibitors." Ann Intern Med 131 (1999): 548
3. Struble K, Piscitelli SC "Syndromes of abnormal fat redistribution and metabolic complications in HIV-infected patients." Am J Health Syst Pharm 56 (1999): 2343-8
4. Tsiodras S, Mantzoros C, Hammer S, Samore M "Effects of protease inhibitors on hyperglycemia, hyperlipidemia, and lipodystrophy - A 5-year cohort study." Arch Intern Med 160 (2000): 2050-6
5. "Product Information. Kaletra (lopinavir-ritonavir)." Abbott Pharmaceutical (2001):
6. "Product Information. Fortovase (saquinavir)." Roche Laboratories (2001):
7. Noor MA, Lo JC, Mulligan K, Schwarz JM, Halvorsen RA, Schambelan M, Grunfeld C "Metabolic effects of indinavir in healthy HIV-seronegative men." Aids 15 (2001): f11-8
8. Costa A, Pulido F, Rubio R, Cepeda C, Torralba M, Costa JR "Lipid changes in HIV-infected patients who started rescue therapy with an amprenavir/ritonavir-based highly active antiretroviral therapy." AIDS 16 (2002): 1983-4
9. "Product Information. Reyataz (atazanavir)." Bristol-Myers Squibb (2003):
10. "Product Information. Lexiva (fosamprenavir)." GlaxoSmithKline (2003):
11. "Product Information. Aptivus (tipranavir)." Boehringer-Ingelheim (2005):

Therapeutic duplication

Drug classes that overlap with Lopinavir + Ritonavir, so taking both doubles up the same effect. This source publishes no per-row citations for duplication.

antiviral boosters
The recommended maximum number of medicines in the 'antiviral boosters' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antiviral boosters' category.
Example product in the source data (US market): Prezcobix
antiviral boosters
The recommended maximum number of medicines in the 'antiviral boosters' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antiviral boosters' category.
Example product in the source data (US market): Evotaz
antiviral boosters
The recommended maximum number of medicines in the 'antiviral boosters' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antiviral boosters' category.
Example product in the source data (US market): Symtuza
antiviral boosters
The recommended maximum number of medicines in the 'antiviral boosters' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antiviral boosters' category.
Example product in the source data (US market): Stribild
antiviral boosters
The recommended maximum number of medicines in the 'antiviral boosters' category to be taken concurrently is usually one.Your list includes two medicines belonging to the 'antiviral boosters' category.
Example product in the source data (US market): Genvoya

Medicines

Food & lifestyle

high-fat foods

Conditions

Hemophilia A

Liver Diseases

Heart Block

Hyperglycemia

Hyperlipidemias

Therapeutic duplication

antiviral boosters

antiviral boosters

antiviral boosters

antiviral boosters

antiviral boosters